{"id":560849,"date":"2026-07-04T02:00:00","date_gmt":"2026-07-04T00:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/tratamientos-orales-con-glp-1-attain-1-y-oasis-4-el-siguiente-paso\/"},"modified":"2026-07-10T17:58:36","modified_gmt":"2026-07-10T15:58:36","slug":"tratamientos-orales-con-glp-1-attain-1-y-oasis-4-el-siguiente-paso","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/tratamientos-orales-con-glp-1-attain-1-y-oasis-4-el-siguiente-paso\/","title":{"rendered":"Tratamientos orales con GLP-1: ATTAIN-1 y OASIS-4: el siguiente paso"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Los agonistas inyectables del receptor del GLP-1 y el agonista dual GIP\/GLP-1 tirzepatida han redefinido el tratamiento farmacol\u00f3gico de la obesidad y han logrado, en los estudios, reducciones de peso del orden del 15 al 20 %. No obstante, su aplicaci\u00f3n en la pr\u00e1ctica sigue siendo limitada, debido a la propia inyecci\u00f3n, a los costes, a los requisitos de la cadena de fr\u00edo, a los cuellos de botella en el suministro y a una adherencia al tratamiento a menudo insatisfactoria. La Organizaci\u00f3n Mundial de la Salud ha se\u00f1alado claramente esta disparidad para el a\u00f1o 2025: incluso con una r\u00e1pida ampliaci\u00f3n de la producci\u00f3n, se prev\u00e9 que, de aqu\u00ed a 2030, menos del 10 % de las personas que podr\u00edan recibir tratamiento tengan realmente acceso a estas sustancias. Por lo tanto, una <em>opci\u00f3n oral <\/em>eficaz y f\u00e1cilmente escalable no solo resuelve una cuesti\u00f3n de comodidad, sino que subsana una carencia fundamental en la atenci\u00f3n sanitaria.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Ftratamientos-orales-con-glp-1-attain-1-y-oasis-4-el-siguiente-paso%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Los agonistas inyectables del receptor del GLP-1 y el agonista dual GIP\/GLP-1 tirzepatida han redefinido el tratamiento farmacol\u00f3gico de la obesidad y han logrado, en los estudios, reducciones de peso&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Ftratamientos-orales-con-glp-1-attain-1-y-oasis-4-el-siguiente-paso%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":560850,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Tratamiento de la obesidad","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11552,11352,11475,11478,11288,11354,11430],"tags":[95560,19695,15601,95559,39394],"powerkit_post_featured":[],"class_list":["post-560849","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-es","category-endocrinologia-y-diabetologia","category-estudios","category-formacion-continua","category-medicina-interna-general","category-nutricion","category-prevencion-y-asistencia-sanitaria","tag-attain-1","tag-glp-1-es","tag-moleculas-pequenas","tag-oasis-4","tag-peptido","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-24 11:41:21","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=560849"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560849\/revisions"}],"predecessor-version":[{"id":560851,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560849\/revisions\/560851"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media\/560850"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=560849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=560849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=560849"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=560849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}